As Big Tobacco companies pivot away from combustible products to less harmful nicotine alternatives, they’re finding new challenges in their relationships with regulators.
Sal Mancuso, the CEO of Altria Group, which owns cigarette and cigar brands like Marlboro and Black & Mild, explained at the Fortune 500 Innovation Forum in Detroit on Monday that competing in a Food and Drug Administration-regulated industry brings with it both an added sense of responsibility to consumers, and hurdles in competing with other businesses in the space. Mancuso said that Altria’s On! nicotine pouch brand is a key innovation for the company, but regulations have slowed growth.
The Marlboro-maker announced its Moving Beyond Smoking initiative in 2023 as more consumers move away from cigarettes, putting a renewed focus on smoke-free alternatives to cigarettes such as NJOY vapes and On! nicotine pouches, which are competing with Philip Morris’s Zyn.
“You can call us the underdog in the pouch category today, but our intention is to lead the pouch category over the long term,” Mancuso told Fortune Executive Editorial Director Diane Brady. “When you think about what’s maybe getting in the way, there’s a couple of factors: One is just the misperception that nicotine is what causes harm from tobacco use. Most of the harm is from combustion, so clarifying that misperception is important. And then we are regulated by the FDA. When you’re in the nicotine business, responsibility needs to be at the heart of everything you do.”
Altria, through its subsidiaries Helix Innovations and NJOY, sued the FDA in September, claiming the agency blocked newer nicotine products from reaching the market through its review process, which the nicotine company is seeking to overhaul. Through the Premarket Tobacco Product Application (PMTA), the FDA is legally required to review new tobacco products before they reach market and decide if the product provides an overall public health benefit within 180 days of submitting an application. Altria claims the FDA has failed to meet that deadline, and that the regulator’s red tape and bureaucracy stalled newer On! products from reaching the market, while foreign competitors flood store shelves.
The FDA said it would consider revisions to the PMTA and consider new rules as the market continues to change, and last month, U.S. District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and the plaintiffs to pause litigation.
Mancuso explained that Altria sued the FDA because it needed enforcement against illicit products. Reiterating what was in the lawsuit, he said what should take the FDA six months to review was taking six years in some cases, allowing illegal products, particularly from China, from not just taking market share, but also skirting standards Mancuso believes the FDA should keep in place to protect the safety of the consumer. He claimed competing overseas products are marketed in vape shops as made in the U.S.A, but are mislabeled.
“Quite frankly, the regulations are broken,” Mancuso said. “There’s too much information. We still want a high standard, but it should be streamlined.
“Guidance is not durable,” he added. “It can be torn up immediately. What we want is more rapid authorization, so that consumers have product choices that they can choose from.”
The regulatory landscape of nicotine is similar in some ways to how cannabis is being introduced and regulated in U.S. markets, Mancuso suggested, such that the substance is legal in half of U.S. states, but there’s no federal standard, creating a “hodgepodge” of regulations.
“Regulations are hard for any business,” Mancuso said. “At the very least, it should be an even playing field, not a playing field where bad actors are in a better position than responsible companies like ours.

